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Emerging antiviral resistant strains of influenza A virus are greatly limiting the therapies available to stop aggressive
infections. Genome changes that confer resistance to the two classes of approved antivirals have been identified in
circulating influenza A viruses. It is only a matter of time before the currently approved influenza A antivirals are
rendered ineffective, emphasizing the need for additional influenza antiviral therapies. This review highlights the
current state of antiviral resistance in circulating and highly pathogenic influenza A viruses and explores potential
antiviral targets within the proteins of the influenza A virus ribonucleoprotein (vRNP) complex, drawing attention to
the viral protein activities and interactions that play an indispensable role in the influenza life cycle. Investigation of
small molecule inhibition, accelerated by the use of crystal structures of vRNP proteins, has provided important
information about viral protein domains and interactions, and has revealed many promising antiviral drug
candidates discussed in this review.
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Influenza A viruses are infectious agents spread through
contact or aerosol droplets that result in a seasonal re-
spiratory illness which can potentially lead to death.
Highly transmissible influenza A viruses can reach pan-
demic proportions as seen in 1918, 1957, 1968, and
2009. The natural reservoir for influenza A viruses are
aquatic birds, but many animals are susceptible to infec-
tion, including swine and humans. While humans are
not readily infected with avian influenza viruses, in rare
cases direct avian to human transmission has occurred.
Swine are readily susceptible to avian, swine, and human
influenza subtypes and provide a vessel for genome reas-
sortment among different subtypes of the virus. The in-
fluenza A virus genome is made up of eight negative
sense RNA segments (vRNA). Reassortment of genome
segments between different influenza A subtypes can
yield new influenza A subtypes that have potential to
cause a human influenza pandemic. While the 1918 pan-
demic virus was found to be of wholly avian origin, the* Correspondence: lnewcomb@.csusb.edu
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unless otherwise stated.1957 and 1968 pandemics contained segments of avian
and human origin [1]. In this case it is unclear if swine or
human were the vessel of reassortment; although swine
are more readily infected with avian influenzas, thus pro-
viding more opportunity for reassortment, humans can be
infected with avian influenza, and although rare, reassort-
ment within a human host remains a possibility [1]. The
2009 influenza H1N1 pandemic contained segments of
avian, swine, and human origin and was thus a triple reas-
sortant that likely emerged from swine [2].
Influenza infection is typically prevented by annual
vaccination. However, vaccines are not useful after infec-
tion or against emerging subtypes of influenza not tar-
geted during vaccine production, as witnessed with the
novel H1N1 pandemic in 2009. Therefore, antivirals that
target specific proteins to inhibit virus replication are
necessary to stave the spread of an emerging pandemic.
The eight genome segments of influenza A virus encode
10 different coding mRNAs by way of alternate splicing
[3] which result in over 12 proteins due to alternate
translation [4-7]. Two viral segments code for the sur-
face proteins HA and NA for which influenza subtypes
are named. Three viral gene segments encode the RNAtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Davis et al. Virology Journal 2014, 11:167 Page 2 of 10
http://www.virologyj.com/content/11/1/167dependent RNA polymerase complex: PA, PB1, and PB2.
At least two of these genome segments also encode al-
ternate translation products including PB1-F2, PB1-N40,
PA-X, PA-N155 and PA-N182 [4-7]. One segment en-
codes the nucleoprotein NP. Two segments, M and NS,
undergo alternate splicing to produce NS1, NS2 (NEP),
M1 and M2 proteins. With so many viral protein interac-
tions required in various stages of the influenza life cycle,
there are numerous potential target sites for antiviral
treatments. Current antivirals target the activities of M2
and NA, but resistance is emerging. This review catalogs
the current state of influenza antiviral resistance and de-
scribes promising new molecules targeting proteins within
the viral ribonucleoprotein (vRNP), the complex com-
prised of the viral RNA genome, the RNA-dependent
RNA polymerase (RdRP), and nucleoprotein (NP).
Review
Current antivirals and resistance
The current antivirals approved by the FDA are, in order
of their release, Symmetra (amantadine), Flumadine
(rimantadine), Relenza (zanamivir), and Tamiflu (oselta-
mivir). Amantadine and rimantadine are adamantane de-
rivatives that target and inhibit the M2 ion channel. The
M2 ion channel is an integral membrane protein respon-
sible for release of vRNPs during infection [8]. By bind-
ing to the M2 ion channel, amantadine and rimantadine
inhibit vRNP release and thus viral replication [9,10].
The antivirals zanamivir and oseltamivir are NA or neur-
aminidase inhibitors. NA activity is required to release
new virions from infected cells [11]. These drugs inhibit
virus release from infected host cells by binding to the
active site of the NA protein [12,13].
Resistance against both classes of influenza antiviral
treatments has been documented. Resistance to M2 ion
channel inhibitors occurs via a triple amino acid deletion
at residues 28–31 or single amino acid substitutions in
the transmembrane region spanning residues 26–31 of
the M2 protein [14,15]. 100% of H3N2 influenza A vi-
ruses circulating in 2009–2010 and 99.8% of 2009 pan-
demic H1N1 were resistant to adamantanes [16]. Many
resistant H1N1 isolates encoded V27A substitution,
while resistant H3N2 isolates were found to encode sub-
stitutions at L26F, V27A, A30T, S31N, or G34E [17]. Resis-
tance to adamantanes in H7N9 has also been documented
and is acquired by substitution S31N [18].
Resistance to NA inhibitors is less common as this class
of inhibitors was developed later. For example, 98.9% of
tested 2009 H1N1 viruses remained susceptible to oselta-
mivir, 100% of 2009 H1N1 viruses tested remained sus-
ceptible to zanamivir [19], 100% of influenza A H3N2
tested remained susceptible to both oseltamivir and zana-
mivir for the 2012–2013 season [20]. However, multiple
single amino acid changes in NA alter susceptibility to theapproved neuraminidase inhibitors. Residues V116, I117,
E119, Q136, K150, D151, D199, I223, H275, and N295
were selected to monitor for changes that confer drug re-
sistance or reduce efficacy of the antivirals [21]. Resistance
evolves during treatment, via single amino acid substitu-
tions including changes to amino acids mentioned above
such as E119V, I223R [22,23], and H275Y [24], but also
R292K and N294S [25]. Pandemic H1N1 2009 isolates
with a substitution at I223R were resistant to neurami-
nidase inhibitors in addition to M2 ion channel inhibitors
as discussed above [23]. Thus, while NA inhibitors are
currently still viable to combat most emerging influenza
threats, it is only a matter of time before resistance takes
hold as with the adamantanes, rendering both current
antiviral therapies ineffective against an emerging influ-
enza threat.
Most worrisome is resistance reported among Highly
Pathogenic Avian Influenza (HPAI) subtypes that could
spur the next pandemic. Avian subtypes such as H5N1,
H7N9, and H7N7 have all resulted in human infection.
The H5N1 infections result in high morbidity at ~60%,
while H7N9 and H7N7 have seen more variability in
outcome of human infection [26]. Fortunately none of
these subtypes have gained the ability to transmit readily
from human to human, but unfortunately, these strains
already have antiviral resistant isolates reported. For ex-
ample, all H7N9 isolates tested were resistant to ada-
mantanes via the S31N substitution in the M2 protein
[27], while some H7N9 exhibit high resistance to oselta-
mivir, mid-resistance to peramivir, and low-resistance to
zanamivir via the NA R292K substitution [28]. Also of
grave concern are H5N1 isolates that encode M2 changes
to confer resistance to adamantanes and NA changes that
reduce susceptibility to neuraminidase inhibitors [29].
With many circulating antiviral resistant strains and the
consequences of a looming virulent influenza pandemic,
novel antiviral targets must be investigated so that new
therapies can be developed before such a catastrophic
event occurs. One promising novel viral target is the
viral ribonucleoprotein or vRNP. Figure 1 depicts vRNP
interactions and activities targeted by new anti-
influenza candidates.
vRNP: viral ribonucleoprotein
During infection eight vRNPs, containing the eight differ-
ent vRNA genome segments, are released and imported
into the nucleus to transcribe and replicate the vRNA.
Transcription of the viral genome proceeds via a cellular
capped-mRNA primer cleaved from host mRNA by the
viral polymerase [30]. Unlike other RNA genome viruses,
which typically replicate in the cytoplasm, influenza must
enter the nucleus to steal nascent host capped mRNAs for
use as primers in transcription. The polymerase subunit
PA provides the endonuclease activity [31,32], while PB2
Figure 1 Antiviral targets of viral ribonucleoprotein. Anti-influenza
candidates include small molecule inhibitors that disrupt critical
functions or interactions within the vRNP. This figure provides a
summary of the promising anti-influenza candidates discussed in
this review.
Figure 2 Antiviral targets of nucleoprotein. Analysis of NP
monomer crystal structure extracted from NP trimer crystal structure
“2IQH” [39] using Deep View-Swiss-PdbViewer 4.0. Residue color
determined by accessibility. Greatest to least accessible as follows:
red, orange, yellow, green, light blue, and dark blue. Residue 289 is
the proposed site of interaction with the antiviral compound
nucleozin [41]. An intermolecular salt bridge formed by residues 339
and 416 of NP is essential for oligomerization and can be disrupted
by small molecule inhibitors [42].
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[33]. Polymerization of the viral mRNA transcript pro-
ceeds via the PB1 subunit until the polyadenylation signal
of repetitive U residues result in stuttering by the viral
RdRP and yields the poly(A) tail, terminating transcription
[34]. Transcripts of two influenza genome segments, M
and NS, undergo alternative splicing to produce M1, M2,
NS1 and NS2 (NEP); utilization of host nuclear splicing
machinery is another reason for nuclear localization of in-
fluenza vRNPs.
Viral replication occurs de novo, without a primer
[35]. In the host cell viral RNA replication occurs after
translation of viral RdRP and NP proteins. Evidence sug-
gests a model wherein the resident RdRP of the vRNP is
responsible for transcription, while a soluble RdRP is re-
sponsible for replication from the vRNA template [36].
There are two primer-independent steps of viral replica-
tion. First the vRNA template is used to synthesize a
full-length complementary (cRNA), which is then repli-
cated to yield progeny vRNA that can be transcribed to
mRNA or packaged into new virions during later stages
of the viral replication cycle. NP is required for anti-
termination at the poly U stretch to allow for replication
of full length cRNA [37]. NP encapsidates both cRNA and
vRNA replication products and is necessary for genome
length functional cRNPs and vRNPs, respectively [38].
NP: nucleoprotein
The crystal structure of NP [39] (Figure 2) reveals two
regions termed the body domain and the head domain,
between which lies a deep groove comprised of posi-
tively charged basic amino acid residues that form ionic
bonds with the negatively charged phosphate backbone
of viral cRNA and vRNA. On the opposing side of the
RNA binding groove lies a tail loop for oligomerizationwith other NP monomers. The tail loop of NP spans resi-
dues 402–428, and is critical to NP oligomerization and
RNA binding, as shown through a tail loop deletion mutant
that produced primarily monomeric NP unable to oligo-
merize and bind RNA [40]. Another crucial oligomerization
interaction occurs through a salt bridge between residue
339 of one NP monomer and residue 416 of another NP
monomer [39,41,42]. Mutational studies disrupting this salt
bridge led to inhibition of viral RNA synthesis in vitro, fur-
ther highlighting the importance of the interaction between
NP molecules for vRNP function [42].
However, NP is more than a structural RNA binding
protein. NP associates with viral proteins such as PB1
and PB2 [43], and M1 [44], in addition to several cellular
factors [45]. Interaction between NP and the RdRP en-
hanced unprimed replication in vitro, suggesting the
NP-RdRP interaction may regulate the switch from pri-
mer initiated transcription to unprimed replication [46].
Interaction of NP with the polymerase subunits was
crudely mapped to regions within both the body and
head domain of the NP crystal structure [43,39]. NP-PB2
and NP-PB1 associations were confirmed through co-
immunoprecipitation assays in the absence of other viral
factors [43]. The NP-PB2 interaction was refined to resi-
due 627 and 630 of PB2 and residue 150 of NP, with the
strength of NP-PB2 interaction directly correlated with
RdRP activity [47]. Residue R150 of NP is highly con-
served and vital for normal viral RNA synthesis during
influenza A WSN infection of MDCK cells [48]. As dis-
cussed below, PB2 residue 627 is a well-characterized host
range determinant [49,50]. Additional NP mutational
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dues of the head domain at 204, 207, and 208 disrupt
interaction with the viral polymerase and inhibit viral
RNA synthesis [51]. Cryo-EM and cryo-electron tomog-
raphy data of native vRNPs in packaged virions revealed
two different conformations of polymerase interaction
with NP within the vRNP [52]. Together, the evidence
points to multiple residues on NP that participate in NP-
RdRP interactions. The protein sequence homology of NP
is a staggering ninety percent among influenza A isolates
[53], with the described interaction domains exhibiting
even greater homology, highlighting the potential of dis-
rupting NP interactions as an effective antiviral target.
RdRP: RNA dependent RNA polymerase
The influenza A virus RNA dependent RNA polymerase
is a heterotrimer comprised of PA, PB2, and PB1.
PA
While PA is required for both viral transcription and
replication, the major role attributed to PA during influ-
enza infection is the endonuclease activity needed to
steal capped primers for viral transcription initiation in
the nucleus of a host cell [30-32,54]. Several highly con-
served endonuclease active sites span the N-terminal
209 residues of PA [32]. Alanine screening of amino
acids 102 through 134 revealed residues necessary for
endonuclease activity [55]. Substitutions D108A and
K134A individually inhibited both endonuclease activity
and transcription in vitro [31,55]. PA also makes con-
tacts with both vRNA and cRNA promoters between
residues 100–180, though the precise residues involved
are debated [55-57]. In addition, PA has documented
protease activity with Ser 624 defined as the active site
[55], though the purpose of this activity remains poorly
understood. The essential endonuclease activity of PA is
an excellent target for antivirals.
PB2
PB2 contains the cap-binding domain, which recognizes
the capped structure on nascent host mRNAs to be
cleaved by the endonuclease site of PA [33]. PB2 resi-
dues 318–483 comprise this domain and contain two
aromatic amino acids at positions 363 and 404 necessary
for cap-binding [58,59]. The cap-binding domain of PB2
may also mediate interaction between PB1 and PB2, spe-
cifically a loop consisting of residues 421–427 of PB2,
which is essential for cap-dependent transcription but
not cap-binding, as determined by a deletion mutant
[59]. Cap-binding and capped RNA primed transcription
are essential activities for influenza that can be targeted
by novel antivirals.
PB2 also makes contacts with both vRNA and cRNA
promoters in an alpha helix rich region between residues535–684, which form an RNA binding domain [50]. Lo-
cated within this domain is residue 627, a well-
characterized species and pathogenicity determinant for
influenza A viruses [49,50,60-63]. Avian influenza A vi-
ruses encode PB2 with glutamic acid at residue 627,
while human influenza A viruses encode lysine [49].
RNA binding ability of PB2 was linked to the amino acid
encoded at 627, with increased RNA binding shown for
PB2 proteins containing K627 [50]. Polymerase activity
and interaction of PB2 with NP were also shown to be in-
fluenced by PB2 residue 627, in addition to residue 630
[47]. Characteristic avian PB2 residue E627 must also
encode R630 for proper polymerase activity and co-
immunoprecipitation with NP [47]. Characteristic hu-
man PB2 residue K627 requires G630 for proper poly-
merase activity and co-immunoprecipitation with NP
[47]. Residue 627 of PB2 influences binding of NP and
RNA, two interactions essential for viral RNA synthesis,
making this region of PB2 a favorable target for new
antivirals.
PB1
PB1 is the RNA polymerizing subunit of the RNA
dependent RNA polymerase. Residues 1–83 and 494–
757 of PB1 contribute to vRNA template interaction
through in vitro analysis of PB1 deletion mutants [64].
PB1 interacts with PA through its N terminal domain
and PB2 through its C terminal domain, thus forming
the functional RNA dependent RNA polymerase [65-68].
RNA dependent RNA polymerase activity of RNA vi-
ruses represents a viral activity that can be targeted by
antivirals.
The C-terminal domain of PB1 (678–757) and the N-
terminal domain of PB2 (1–37) were defined as the re-
gions responsible for PB1-PB2 interaction and were
crystalized to facilitate further investigation [66,69].
Crystal structure of this interaction reveals all contacts
occur through helix 1 of PB2 (residues 1–12), which is
essential for proper RNA polymerase activity [69]. The
PB1-PB2 protein interface is of great interest as an anti-
viral target due to the conservation of these domains in
both human and avian viruses [69].
The N-terminus of PB1 (1–80) interacts with the C
terminal region of PA consisting of residues 239–716
[66,70]. Interaction surfaces of both PB1 and PA are
highly conserved [68,71,72]. The crystal structure of this
interaction reveals PB1 N terminal 25 residues occupy a
C-terminal hydrophobic groove of PA [68] (Figure 3).
The C-terminal domain of PA has been referred to as a
“dragon’s head” that holds the N-terminus of PB1 in its
“jaws” [68]. A peptide analog of the N-terminal 25
amino acids of PB1 blocks formation of the RNA
dependent RNA polymerase complex resulting in no
viral replication [68,73]. These studies demonstrate the
Figure 3 PA-PB1 interaction site is an antiviral target. Analysis of
the PAC-PB1N crystal structure “3CM8” [68] using Deep View-Swiss-
PdbViewer 4.0. Residues 1–16 of PB1 (red) are shown in interaction
with residues 258–716 of PA (blue). Many small molecule inhibitors
of PA resemble the N terminus of PB1 and bind in the hydrophobic
pocket blocking essential interactions between the polymerase
subunits [68,73,95].
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vital for viral RNA synthesis, making this interaction a
potential target for novel antivirals.
New antivirals targeting influenza vRNP
The critical roles of the influenza vRNP for viral RNA
synthesis make activities of the vRNP, such as cap-
snatching and RNA polymerization, excellent antiviral
targets. A recently discovered nucleotide analog prefer-
entially utilized by viral RNA dependent RNA polymer-
ases including influenza vRNP, is under study as a
promising antiviral therapy targeting the activity of viral
RNA dependent RNA polymerases [74]. Further, the
multiple essential interactions of the vRNP, such as with
each other to form the RNA dependent RNA polymer-
ase heterodimer, with host capped mRNAs to obtain
primers for viral transcription, and with NP to regulate
and enhance RNA replication, coupled with high conser-
vation of these domains among influenza subtypes, make
the proteins of the vRNP excellent targets for small mol-
ecule inhibitors with broad efficacy against multiple in-
fluenza A subtypes.
Ribonucleotide analogs
Favipiravir is a 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
molecule (also known as T-705) that upon phosphorylation
becomes favipiravir-ribofuranosyl-5’-triphosphate (RTP)
and inhibits many viral RNA dependent RNA polymerases
[75]. Favipiravir is effective against influenza A, influenza B,
influenza C, hantaviruses, flaviviruses, noroviruses, andmost recently ebola viruses [74-76]. The T-705 RTP is erro-
neously interpreted as a purine nucleotide by the viral poly-
merase during RNA elongation [75,77]. Once incorporated
into the elongating viral RNA, the analog may hinder
strand extension [77]. The antiviral activity of Favipiravir in-
cludes influenza A(H3N2), A(H1N1), A(H5N1), A(H7N9),
and strains bearing resistance to both classes of the current
FDA approved influenza antivirals [74,75,78].
The 50% inhibitory concentration (IC50) of favipiravir
for influenza, determined by plaque reduction assay, was
0.013-0.48 μg/ml with no cytotoxic effect up to 1000 μg/
ml [74]. Human DNA polymerase α, β, or γ with 1000 μM
of favipiravir showed little sign of inhibition [79] and hu-
man RNA polymerase II had an IC50 of 905 μM of favipir-
avir [80]. Therefore, the IC50 of host polymerases is well
over 2000 times greater then the IC50 for influenza vRNP,
making favipiravir highly selective for influenza vRNP
[75]. Favipiravir for influenza therapy has finished two
Phase II clinical trials in the United States and one Phase
III clinical trial in Japan [75]. Favipiravir is a favorable can-
didate for a broadly effective antiviral therapy targeting
RNA viruses with RNA dependent RNA polymerases that
preferentially incorporate favipiravir in RNA synthesis. It
is not yet clear if or how quickly influenza vRNP will
evolve resistance to this nucleotide analog, but based on
HBV and approved nucleotide analog therapies [81], as
with any antiviral therapy, if resistance is possible, it will
eventually develop, stressing the need to consistently look
for novel antiviral targets and therapies.
Small molecule inhibitors
Unlike nucleotide analog therapies, small molecule in-
hibitors work by interaction with a viral protein to block
a function or interaction and inhibit viral replication.
Crystal structure data provides much information to
identify small molecules with potential to bind a domain
of the target protein and inhibit essential functions or
interactions. Small molecules that target conserved re-
gions are likely to have the best efficacy against multiple
subtypes. Further, conserved regions are less likely to
tolerate mutation and evolve a viable virus with resist-
ance to the small molecule.
Targeting NP
Nucleozin is a small molecule inhibitor of NP that works
by promoting NP oligomerization, blocking nuclear
entry through aggregation of NP molecules at the nu-
clear membrane [41] and inducing vRNP aggregation
during cytoplasmic trafficking [82]. Molecular docking
models identified two proposed nucleozin interaction
sites at residue 289 and 309 of NP [41]. Both residues
participate to stabilize the interaction; a tyrosine at resi-
due 289 forms aromatic ring stacking with nucleozin,
while an asparagine at residue 309 shares a hydrogen
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sistant encoded a histidine in place of a tyrosine at resi-
due 289 of NP [41]. From the crystal structure of NP,
residue 289 is relatively accessible to interact with
nucleozin (Figure 2) [39,41]. The 289H NP variant likely
disrupts a critical point of interaction between NP and
nucleozin. Sequence analysis of the NP gene of 3,881 in-
fluenza strains revealed Y289H substitution in 527
strains. Unfortunately the A(H1N1)pdm09 strain was
shown to contain this single amino acid alteration, signi-
fying it as a nucleozin resistant strain [41]. Nucleozin
demonstrated a 50% effective concentration (EC50) of
only 0.069 μM against influenza with 50% cytotoxic con-
centration greater than 250 μM [41]. Thus nucleozin still
holds potential as a potent antiviral for strains of influ-
enza housing a tyrosine at residue 289 [41]. In addition
to nucleozin, there are several other aryl piperazine
amide compounds discovered in parallel that target NP
and inhibit virus replication in the same manner
[41,83-85]. Cianci et al. provide a detailed review into
the efficacy of aryl piperazine amides, including nucleo-
zin, as NP inhibitors [85]. Further analysis of these com-
pounds could lead to the synthesis of an optimized aryl
piperazine amide inhibitor of viral replication, even
against the circulating nucleozin resistant strains of
influenza.
The essential salt bridge for NP oligomerization at res-
idues 339 and 416 was targeted for disruption by small
molecule inhibitors (Figure 2) [42]. Peptides that
mimicked the NP tail loop (residues 402–428) bound
in the tail loop binding pocket and inhibited NP
oligomerization, resulting in decreased viral replication
by greater than fifty percent [42]. Random virtual
screening of small molecules identified four compounds
(termed # 3, 7, 12, and 23) that interrupt NP
oligomerization and decrease viral replication [42]. The
IC50 of compounds 3, 7, 12, and 23 ranged from 2.4 to
118 μM in cells challenged with influenza A/WSN/33
for nine hours at a multiplicity of infection (MOI) of 0.2
[42]. Although the targeted NP domain is highly con-
served, more research will need to be carried out to en-
sure little to no development of resistance to the
compounds. Importantly, cytotoxicity of these com-
pounds will need to be assessed before they can be of
use as antiviral therapies.
Mycalamide A is an antiviral and antitumor compound
isolated from Mycale sponges but is unfortunately toxic
to cells [86]. A photo-cross-linked chemical array identi-
fied analogs of mycalamide A that possess the ability to
bind NP [87]. One compound inhibited viral replication
up to 77% in a plaque assay using influenza virus (A/
WSN/33) with no cytotoxic effect [87]. Binding affinity
of the analogs was greatest within the N-terminal 110
amino acids of NP [87]. Although the mechanism ofinhibition remains uncharacterized, the N-terminus of
NP contains an important non-canonical nuclear
localization signal (NLS) [88,89] and interacts with host
RNA processing factors UAP56 and URH49 [90,91] pro-
posed to enhance RNA replication [92]. More research
is needed on these compounds to elucidate the mechan-
ism of inhibition and determine if or how quickly influ-
enza NP will evolve resistance.
Naproxen is an over the counter nonsteroidal anti-
inflammatory drug that inhibits NP from associating
with RNA in the RNA binding groove (Figure 2) [93].
From several molecular docking studies, residues Y148,
Q149, R150, R355, R361, and F489 are believed to
stabilize naproxen binding to NP [93]. Naproxen acts se-
lectively upon monomeric NP and was shown to protect
MDCK cells and mice from a viral challenge at an MOI
of 10−2 - 10−3 or 50–2,000 PFU respectively, with little
to no cytotoxic effects [93]. Subtypes of H1N1 and
H3N2 were both susceptible to inhibition and treatment
resulted in efficient protection from viral challenge with
either subtype [93]. No escape mutant viruses were pro-
duced in response to 500 μM naproxen treatment in
cells after six passages [93]. Within this experiment the
mode of delivery for naproxen was intraperitoneal injec-
tion or intranasal treatment in mice that displayed an
EC50 of 40 mg/kg [93]. Naproxen is currently used as an
oral medication with a recommended dosage of 220 mg
every 8 hours for pain. Naproxen is not currently used
as an antiviral but could be optimized for antiviral use
through further experimentation and improved drug
design.
Targeting PA-PB1 interaction
Inhibitors of the PA-PB1 interaction are numerous [94].
Compound 1 was discovered through in silico screening
[94] using the crystal structure of PAC-PB1N (Figure 3)
[68]. The hydrophobic pocket of PA houses compound 1
according to molecular docking studies, and inhibition
of PA-PB1 interaction was demonstrated through ELISA
and immunoprecipitation of PA [94]. Compound 1
inhibited RNA polymerase activity in a dose-dependent
manner with an IC50 of about 18 μM assessed in a mini-
replicon assay using a firefly luciferase reporter gene,
with no significant cytotoxic effect up to concentrations
of 250–1000 μM [94]. Compound 1 inhibited viral repli-
cation in MDCK cells for several influenza A H1N1 and
H3N2 strains, a swine-origin influenza virus, and an
oseltamivir-resistant isolate, with IC50 ranging from 12.2
to 22.5 μM [94].
There are two FDA approved medications that in
addition to their intended use also possess anti-IAV abil-
ities due to their structural similarity with the N ter-
minal domain of PB1 that interacts with the C-terminus
of PA (Figure 3) [95]. Benzbromarone is approved to
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tion of uric acid. Diclazuril is most commonly used in
veterinary medicine as an anti-coccidial. Although these
drugs are FDA approved, appropriate drug dosages for
use against viral challenges would need to be established
before they could be employed for use against influenza
A. Testing for the ability of viruses to gain resistance to
these drugs must also be done. Benzbromarone and
diclazuril could potentially be utilized if an influenza
strain arises that possesses resistance to other antivirals
available [95].
In addition, a compound derived from licorice, 18β-
glycyrrhetinic acid (GHA), is a naturally occurring com-
pound that exhibits some anti-IAV activity attributed to
interaction with the C terminal domain of PA [96]. Mo-
lecular docking studies identified GHA as a ligand to
PAC [96]. GHA decreased polymerase activity 80%, as
assessed by a primer extension assay for cRNA synthesis
[96]. These preliminary findings need to be investigated
further with more informative assays including in vitro
PA-PB1 interaction inhibition study, in vivo polymerase
activity assays in tissue culture, and in vivo infection in
an animal model. There are many small molecules that
mimic the N terminus of PB1 fit in the hydrophobic
groove of PA to inhibit PA-PB1 interaction (Figure 3)
and should be studied further for their potential as an
anti-influenza A treatment.
Targeting PA endonuclease
Fullerene (C60) is a spherical molecule of sixty carbon
atoms that exhibits anti-influenza activity [97]. Full length
PA and an isolated PA endonuclease domain were tested
in an in vitro endonuclease assay in the presence of fuller-
ene derivatives. Seven fullerene derivatives were able to in-
hibit the endonuclease ability of the full length PA and
isolated endonuclease domain [97]. Docking simulations
reveal the fullerene skeleton fits nicely into the endonucle-
ase domain active pocket [97]. MDCK cells were infected
with influenza A H1N1 or H3N2 mixed with 0 to 100 μM
fullerene derivative and immunostained for NP at 24 hours
post infection to reveal significantly less NP in cells in-
fected with virus pre-incubated with fullerene compared
to a DMSO control [97]. Twelve derivatives of fullerene
were tested and resulted in varying efficacy against influ-
enza but showed no cytotoxic effect up to 100 μM [97].
More investigation into the activity and expression of viral
proteins in response to fullerene needs to be conducted.
Importantly, treatment applied post-infection needs to be
investigated. This novel compound exemplifies yet an-
other possible antiviral target within the vRNP.
Targeting PB2 cap-binding domain
Compounds that mimic the 7-methylguanosine moiety
of the 5’ cap of mRNAs may serve as transcriptionalinhibitors. Docking studies of the cap-binding domain of
PB2 revealed 7-alkylguanine derivatives as potential in-
hibitory compounds [98]. Several compounds bind the
cap-binding domain of PB2 with greater affinity than a
biotinylated cap analogue [98]. These compounds should
be further studied and optimized for anti-influenza
activity.
Conclusion
Influenza A virus continues to remain a human menace,
in terms of both human health and global economic
costs. The wide host range of influenza A virus, coupled
with a lack of proofreading activity within the viral RNA
dependent RNA polymerases, and a segmented RNA
genome allowing for segment reassortment, provide in-
fluenza A virus with the ability to evolve rapidly. While
yearly vaccination is protective against the strains and
subtypes predicted to be circulating and represented
during vaccine production, vaccination will not protect
against an unseen, emerging subtype of the virus. Anti-
virals are the first line of defense for an emerging pan-
demic and resistance to current antivirals is already
circulating within influenza A viruses, hastening the re-
solve to identify new antiviral therapies. The viral ribo-
nucleoprotein (vRNP) is essential for viral replication,
making it an ideal target for antivirals. Essential activ-
ities of the vRNP include cap-snatching activity required
for viral mRNA transcription and RNA polymerase ac-
tivity required for viral mRNA transcription and RNA
replication. The interactions required to form functional
vRNPs with these essential activities comprise the most
highly conserved protein domains within influenza A
subtypes. These interaction domains represent ideal tar-
gets for small molecule inhibitors, as these domains are
less likely to tolerate mutations. Combination drug ther-
apy is also a potential means to challenge emerging anti-
viral resistance. The vRNP provides multiple viral
protein targets to reduce selection pressures and emer-
gence of resistant strains. However, if mutations confer-
ring antiviral resistance are tolerated, history dictates
these mutations will be selected by use of the antiviral
and propagate in circulating influenza A viruses. This
means the search for new influenza A antiviral inhibi-
tors should be ongoing until a universal vaccine is
achieved.
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